ReviewMicroorganisms2022
Mixed Fungal Biofilms: From Mycobiota to Devices, a New Challenge on Clinical Practice.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Comparative Assessment of Fungal Biofilm Development on PEEK and PDMS Biomaterials and the Antifungal Potential of TiOMaterials (Basel, Switzerland) · 2026Article
- Biofilm formation efficiency by Candida species isolated from gastric mucosa of intragastric balloon patient under extremely low pH.Folia microbiologica · 2026Article
- Preliminary Evaluation of Gemini-Surfactant-Based Formulations for Antifungal Seed Treatment in Wheat.Molecules (Basel, Switzerland) · 2026Article
- Enhanced virulence of mixed-species Candida biofilms isolated from intragastric balloon patient: insights from larval model.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- The Hidden Fortress: A Comprehensive Review of Fungal Biofilms with Emphasis onJournal of fungi (Basel, Switzerland) · 2025Review
- Potable water as a source of intermediate and borderline-resistantJournal of water and health · 2025Article
- An Overview of the Recent Advances in Antimicrobial Resistance.Microorganisms · 2024Review
- Fungal biofilm formation and its regulatory mechanism.Heliyon · 2024Review
- Unveiling the Hidden Perils: A Comprehensive Review of Fungal Infections in Inflatable Penile Prosthesis Surgery.Journal of personalized medicine · 2024Review
- Study on the microbial diversity of ear canal secretions from patients with otomycosis.Frontiers in surgery · 2024Article
- Medical Device-Associated Healthcare Infections: Sterilization and the Potential of Novel Biological Approaches to Ensure Patient Safety.International journal of molecular sciences · 2023Review
- In Vitro and Ex Vivo Biofilm-Forming Ability ofJournal of fungi (Basel, Switzerland) · 2023Article
- Using nanopore sequencing to identify fungi from clinical samples with high phylogenetic resolution.Scientific reports · 2023Article
- Case of Mixed Infection of Toenail Caused byJournal of fungi (Basel, Switzerland) · 2023Article
- Inhibition of Polymicrobial Biofilms ofMarine drugs · 2023Article
- Candida species and oral mycobiota of patients clinically diagnosed with oral thrush.PloS one · 2023Article
- Inhibitory effect of lactobacilli supernatants on biofilm and filamentation ofFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Most current protocols for the diagnosis of fungal infections are based on culture-dependent methods that allow the evaluation of fungal morphology and the identification of the etiologic agent of mycosis. Most current protocols for the diagnosis of fungal infections are based on culture-dependent methods that enable the examination of the fungi for further identification of the etiological agent of the mycosis. The isolation of fungi from pure cultures is typically recommended, as when more than one species is identified, the second agent is considered a contaminant. Fungi mostly survive in highly organized communities that provoke changes in phenotypic profile, increase resistance to antifungals and environmental stresses, and facilitate evasion from the immune system. Mixed fungal biofilms (MFB) harbor more than one fungal species, wherein exchange can occur that potentialize the effects of these virulence factors. However, little is known about MFB and their role in infectious processes, particularly in terms of how each species may synergistically contribute to the pathogenesis. Here, we review fungi present in MFB that are commensals of the human body, forming the mycobiota, and how their participation in MFB affects the maintenance of homeostasis. In addition, we discuss how MFB are formed on both biotic and abiotic surfaces, thus being a significant reservoir of microorganisms that have already been associated in infectious processes of high morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.